PDCD1 and colorectal carcinoma: Preclinically, cabozantinib was able to inhibit tumor growth, augment the immune response, and increase the immunogenicity in the human immune system (HIS)-BRGS mice implanted with MSS-CRC PDX tumors when combined with the anti-PD-1 mAb nivolumab (Lang et al., 2022).